Literature DB >> 25108505

Clinical and mutational spectrum in Korean patients with Rubinstein-Taybi syndrome: the spectrum of brain MRI abnormalities.

Jin Sook Lee1, Christine K Byun1, Hunmin Kim2, Byung Chan Lim1, Hee Hwang2, Ji Eun Choi3, Yong Seung Hwang1, Moon-Woo Seong4, Sung Sup Park4, Ki Joong Kim5, Jong-Hee Chae6.   

Abstract

OBJECTIVE: Rubinstein-Taybi syndrome (RSTS) is one of the neurodevelopmental disorders caused by mutations of epigenetic genes. The CREBBP gene is the most common causative gene, encoding the CREB-binding protein with histone acetyltransferase (HAT) activity, an epigenetic modulator. To date, there have been few reports on the structural abnormalities of the brain in RSTS patients. In addition, there are no reports on the analysis of CREBBP mutations in Korean RSTS patients. PATIENTS AND METHODS: We performed mutational analyses on 16 unrelated patients with RSTS, with diagnosis based on the typical clinical features. Their medical records and brain MRI images were reviewed retrospectively.
RESULTS: Ten of 16 patients (62.5%) had mutations in the CREBBP gene. The mutations included five frameshift mutations (31.2%), two nonsense mutations (12.5%), and three multiexon deletions (18.8%). There were no remarkable significant differences in the clinical features between those with and without a CREBBP mutation, although brain MRI abnormalities were more frequently observed in those with a CREBBP mutation. Seven of 10 patients in whom brain imaging was performed had structural abnormalities, including Chiari malformation type 1, thinning of the corpus callosum, and delayed myelination. There were no differences in delayed development or cognitive impairment between those with and without abnormal brain images, while epilepsy was involved in two patients who had abnormalities on brain MRI images.
CONCLUSIONS: We investigated the spectrum of CREBBP mutations in Korean patients with RSTS for the first time. Eight novel mutations extended the genetic spectrum of CREBBP mutations in RSTS patients. This is also the first study showing the prevalence and spectrum of abnormalities on brain MRI in RSTS patients.
Copyright © 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain MRI abnormalities; CREBBP; Genotype–phenotype; HAT domain; Rubinstein–Taybi syndrome (RSTS)

Mesh:

Substances:

Year:  2014        PMID: 25108505     DOI: 10.1016/j.braindev.2014.07.007

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  10 in total

Review 1.  Chromatin remodeling and epigenetic regulation of oligodendrocyte myelination and myelin repair.

Authors:  Elijah Koreman; Xiaowei Sun; Q Richard Lu
Journal:  Mol Cell Neurosci       Date:  2017-12-15       Impact factor: 4.314

2.  Characterization of 14 novel deletions underlying Rubinstein-Taybi syndrome: an update of the CREBBP deletion repertoire.

Authors:  Daniela Rusconi; Gloria Negri; Patrizia Colapietro; Chiara Picinelli; Donatella Milani; Silvia Spena; Cinzia Magnani; Margherita Cirillo Silengo; Lorena Sorasio; Vaclava Curtisova; Maria Luigia Cavaliere; Paolo Prontera; Gabriela Stangoni; Giovanni Battista Ferrero; Elisa Biamino; Rita Fischetto; Maria Piccione; Paolo Gasparini; Leonardo Salviati; Angelo Selicorni; Palma Finelli; Lidia Larizza; Cristina Gervasini
Journal:  Hum Genet       Date:  2015-03-25       Impact factor: 4.132

Review 3.  Stress and the Emerging Roles of Chromatin Remodeling in Signal Integration and Stable Transmission of Reversible Phenotypes.

Authors:  Ian C G Weaver; Austin C Korgan; Kristen Lee; Ryan V Wheeler; Amos S Hundert; Donna Goguen
Journal:  Front Behav Neurosci       Date:  2017-03-15       Impact factor: 3.558

4.  The transcriptional coactivator and histone acetyltransferase CBP regulates neural precursor cell development and migration.

Authors:  Melanie Schoof; Michael Launspach; Dörthe Holdhof; Lynhda Nguyen; Verena Engel; Severin Filser; Finn Peters; Jana Immenschuh; Malte Hellwig; Judith Niesen; Volker Mall; Birgit Ertl-Wagner; Christian Hagel; Michael Spohn; Beat Lutz; Jan Sedlacik; Daniela Indenbirken; Daniel J Merk; Ulrich Schüller
Journal:  Acta Neuropathol Commun       Date:  2019-12-05       Impact factor: 7.801

5.  Clinical exome sequencing identifies novel CREBBP variants in 18 Chinese Rubinstein-Taybi Syndrome kids with high frequency of polydactyly.

Authors:  Sha Yu; Bingbing Wu; Yanyan Qian; Ping Zhang; Yulan Lu; Xinran Dong; Qing Wang; Xuemei Zhao; Renchao Liu; Wenhao Zhou; Huijun Wang
Journal:  Mol Genet Genomic Med       Date:  2019-10-22       Impact factor: 2.183

6.  New insights into genetic variant spectrum and genotype-phenotype correlations of Rubinstein-Taybi syndrome in 39 CREBBP-positive patients.

Authors:  Virginia Pérez-Grijalba; Alberto García-Oguiza; María López; Judith Armstrong; Sixto García-Miñaur; Jose María Mesa-Latorre; Mar O'Callaghan; Mercé Pineda Marfa; Maria Antonia Ramos-Arroyo; Fernando Santos-Simarro; Verónica Seidel; Elena Domínguez-Garrido
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

7.  A novel CREBBP mutation and its phenotype in a case of Rubinstein-Taybi syndrome.

Authors:  Qian Wang; Cong Wang; Wen Bin Wei; Wei Ning Rong; Xiang Yu Shi
Journal:  BMC Med Genomics       Date:  2022-08-19       Impact factor: 3.622

8.  Brain size regulations by cbp haploinsufficiency evaluated by in-vivo MRI based volumetry.

Authors:  Juan C Ateca-Cabarga; Alejandro Cosa; Vicente Pallarés; José P López-Atalaya; Ángel Barco; Santiago Canals; David Moratal
Journal:  Sci Rep       Date:  2015-11-06       Impact factor: 4.379

Review 9.  Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.

Authors:  Julien Van Gils; Frederique Magdinier; Patricia Fergelot; Didier Lacombe
Journal:  Genes (Basel)       Date:  2021-06-24       Impact factor: 4.096

10.  Genetic and clinical heterogeneity in Korean patients with Rubinstein-Taybi syndrome.

Authors:  Naye Choi; Hwa Young Kim; Byung Chan Lim; Jong-Hee Chae; Soo Yeon Kim; Jung Min Ko
Journal:  Mol Genet Genomic Med       Date:  2021-08-24       Impact factor: 2.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.